docetaxel + oxaliplatin + bevacizumab

A three-drug, intravenous oncology regimen combining the taxane docetaxel, the platinum agent oxaliplatin, and the anti-VEGF monoclonal antibody bevacizumab. Docetaxel stabilizes microtubules to inhibit cell division; oxaliplatin forms DNA crosslinks causing cytotoxicity; bevacizumab binds VEGF-A to inhibit tumor angiogenesis. Investigated in phase II settings including first-line treatment for advanced ovarian, primary peritoneal, or fallopian tube cancer after debulking surgery, with dosing commonly every 3 weeks for six cycles followed by bevacizumab maintenance to complete one year of therapy. Reported toxicities include neutropenia, leukopenia, hypertension, fatigue, nausea, and rare gastrointestinal perforation consistent with bevacizumab class effects.[5][1][7]

Other names

docetaxel oxaliplatin bevacizumabDOC + L-OHP + BEV